Clinical Trials Directory

Trials / Sponsors / Protalix

Protalix

Industry · 16 registered clinical trials — 1 currently recruiting.

StatusTrialPhaseStarted
RecruitingA Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing
Gout
Phase 22025-12-22
CompletedA Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevat
Gout
Phase 12023-03-23
CompletedSafety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks
Fabry Disease
Phase 32017-07-10
WithdrawnStudy to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease
Fabry Disease
Phase 32017-07-01
CompletedSafety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alf
Fabry Disease
Phase 32017-05-17
UnknownOpen Label Study to Assess Safety, PK and Explore Efficacy of OPRX-106 in Patients With Active Mild to Moderat
Ulcerative Colitis
Phase 22016-09-01
CompletedStudy of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function
Fabry Disease
Phase 32016-06-01
UnknownStudy to Evaluate the Safety,Tolerability, Pharmacokinetics and Exploratory Efficacy Parameters of AIR DNase™i
Cystic Fibrosis
Phase 22016-05-01
CompletedSafety, Tolerability and Pharmacokinetics Study of AIR DNAse Administered by Inhalation to Healthy Adult Volun
Cystic Fibrosis (CF)
Phase 12015-12-01
CompletedStudy to Evaluate the Safety and Pharmacokinetics of Oral OPRX-106 (TNFR-Fc Fusion Protein) in Healthy Volunte
Human Volunteer
Phase 12014-07-01
CompletedAn Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112
Gaucher Disease
Phase 22014-04-01
CompletedExtension Study of PRX-102 for up to 60 Months
Fabry Disease
Phase 1 / Phase 22014-01-16
CompletedSafety and Pharmacokinetics of Oral PRX-112 in Gaucher Disease Patients
Gaucher Disease
Phase 12013-03-01
CompletedDose-ranging Study of PRX-102 in Adult Fabry Disease Patients
Fabry Disease
Phase 1 / Phase 22012-10-01
CompletedAn Exploratory Phase 1 Microdose Study of PRX-105
Organophosphate Exposure
EARLY_Phase 12010-03-01
CompletedPhase I Single Dose-Escalation Safety Study of Human Glucocerebrosidase (prGCD)
Gaucher Disease
Phase 12005-11-01